The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | MYMPN: a patient registry removing bias from MPN research
Many clinical trials are skewed towards a certain patient population, resulting in biased data. Here, Ruben Mesa, MD, of UT Health San Antonio Cancer Center, San Antonio, TX, discusses the MYMPN patient registry, which aims to aggregate large quantities of data from patients with myeloproliferative neoplasms (MPNs) across various institutions and trials. He discusses the positive patient recruitment data, as well as his hopes for the future of this resource, suggesting that along with international expansion, biomarker screening could be incorporated. This registry will provide a reliable resource for MPN researchers across the world with a wide-reaching, representative patient sample.
